ARKAY Therapeutics, Logo

(609) 362-6818

Follow Us:LinkedIn

Forefront of Modern Innovative Medicine

Beta Cell Destruction & Restoration

Fluorescence immunostaining of the islets for insulin (beta cell; green) and glucagon (alpha cell; red): Endogenously induced Prostaglandin E2 (Inflammation) dose-dependent destruction of Beta cells in C57BL/6 DIO mice 

Mission Statement

Improve the lifestyle and lifespan of Type 2 diabetes patients by providing long-term sustainable glycemic control.

ARKAY Therapeutics

ARKAY is a pre-IND stage biopharmaceutical company located in East Windsor, NJ. We are currently advancing an innovative first-in class 'Beta-cell-centric' combination product, RK-01 to the clinic. Our immediate goal is to raise capital for a small human PoC controlled clinical study to make ARKAY more attractive to potential Pharma partners. Progressive reduction in pancreatic beta-cell mass and concomitant deterioration of beta-cell function which trigger insulin resistance and hyperglycemia are central to the complex pathophysiology of Type 2 diabetes. RK-01 fills clinically the most important gap that exists in the modalities used for the currently marketed drugs by blocking multiple distinct and overlapping signaling pathways along the immune dysregulation-inflammation-insulin resistance axis that contribute to progressive deterioration of pancreatic beta-cell function. Results obtained from the mouse, rat and human studies indicate that RK-01 maintained or restored beta-cell function; more importantly, reduced the risk of insulin dependence which occurs in spite of intense therapies with current treatment options. According to a recent study that studied long-term trends in antidiabetes drug (ADD) usage in over 1 million newly diagnosed Type 2 diabetes patients aged 18-80 years who initiated any ADD in the United States, the proportion of patients using Metformin as the first-line of therapy increased from 60% in 2005 to 77% in 2016. 48% of patients experienced primary failure with Metformin and 52% of patients experienced secondary failure with second and third add-on drugs (Montvida, O. et al. Diabetes Care, November 6, 2017). RK-01 is custom-designed and formulated to prevent primary and secondary Metformin failure by reducing the risk of insulin dependence. ARKAY's scientfic rationale is supported by the results obtained from translational animal as well as controlled human clinical studies with component drugs in RK-01. Our scientific rationale and product concept have been endorsed by leading diabetes experts and endocrinologists—some of them have joined ARKAY's advisory board. ARKAY is collaborating with Dr. Robert Busch, MD at Albany Medical College to conduct an investigator-initiated first-in-human (FIH) PoC study to evaluate superiority of RK-01 (Valsartan plus Celecoxib dual add-on to Metformin) over Metformin in Type 2 diabetes patients with inadequate glycemic control. Dr. Busch is a diabetes expert; he has served as a Principal Investigator in over 40 clinical studies.

CEOCFO Magazine

"A 'Beta-cell centric' Triple Combination of Metformin, an Angiotensin II Receptor Type I Blocker (ARB) and a selective Cyclooxygenase-2 Inhibitor show promise of providing Long-Term Glycemic Control for Type 2 Diabetes Patients"

The proposed doses of selective Cyclooxygenase-2 (Cox-2) inhibitor, Celecoxib are safe for chronic use in patients with cardiovascular disease risk.

“As the founder and innovator, before I could ask others to invest in my company, I wanted to make sure that I take the risk with my money and establish the proof-of-concept, which we have accomplished already”

Dr. Ravi Kumar
October 3, 2016 Issue

Read Full Article

A New Shift in the Paradigm

"Signaling pathways associated with immune dysregulation, obesity-triggered chronic low-grade inflammation, insulin resistance and cardiovascular disease are intricately intertwined and they are inseparable from each other. For efficient clinical management of insulin resistance, chronic hyperglycemia due to glucose intolerance should not be treated in isolation without treating the causative inflammation. Lowering inflammatory parameters, treating pancreatic beta cell dysfunction, managing hypertension and lowering lipid levels are expected to result in a more rapid improvement in clinical outcomes with optimal glycemic control."

Ravi Kumar, Ph.D.
Founder & CEO

Immune Dysregulation-Inflammation-Insulin Resistance Axis

“I agree that you have an interesting angle and great leadership/SAB advice. There is definitely a lot of unmet medical need in this area and I think that targeting inflammation has a lot of potential. I hope your efforts are highly successful!”

Christopher K. Glass, M.D., Ph.D.
Professor of Cellular & Molecular Medicine
Professor of Medicine

Ben & Wanda Hildyard
Chair in Hereditary Diseases School of Medicine
University of California, San Diego

Striving to End the Epidemic of Type 2 Diabetes

Medicine Tablets

Right now, there are no anti-inflammatory 'Beta-cell-centric' therapies on the market for Type 2 diabetes. Our novel & innovative beta-cell centric product, RK-01 restored efficacy of Metformin in C57BL/6J DIO mice with insulin resistance and pancreatic beta-cell dysfunction. We are on track to bring RK-01 to market by 2020.


ARKAY is advancing the ParamAushadam® (derived from Sanskrit, it means "Perfect Medicine" in English) platform by combining drugs at the appropriate doses along with predetermined modified drug release to achieve optimal therapeutic as well as kinetic synergies.


Discover why now is the best time to partner and collaborate with our biopharmaceutical company. ARKAY Therapeutics is focused on setting the standard for medicine and treatment of Type 2 diabetes and related disorders such as NASH by advancing an innovative 'Beta-cell-centric' platform.


Invest in a healthier future by becoming a key stakeholder today at ARKAY Therapeutics

Call (609) 362-6818

About Us

With the numbers and cases of diabetes always on the rise with no end in sight, our biopharmaceutical company in East Windsor, New Jersey, decided to take action and do something about this global epidemic. Today, ARKAY Therapeutics is dedicated to developing and commercializing innovative medicines for Type 2 diabetes and preventing the onset of Type 2 diabetes in prediabetic patients.

More than 370 million people worldwide and 26 million people in the U.S. alone suffer from Type 2 diabetes. The disease is not successfully controlled in almost 50% of patients, according to American Diabetes Association.

The potential impact of our diabetes medicine has enormous medical and financial implications. This is an avenue that investors can’t afford to miss.

Learn More About ARKAY Therapeutics

More Than 30 Years of BioMedical Experience


Thank you for your interest. For questions or comments, please use the information listed here. We look forward to hearing from you soon.

(609) 362-6818

Hours of Operation
Reach Us via Email 24 Hours a Day, 7 Days a Week

Service Area
Open to Investors Worldwide